Elite Pharma reports FY2026 revenue of $148.9M (+77% YoY), operating income $49.1M (+151%)

ELITE PHARMACEUTICALS INC /NV/

Consolidated revenue $148.9M, up $64.8M (77%) vs prior year; operating profit $49.1M, up $29.5M (151%).
Growth driven by full-year contribution of Lisdexamfetamine, plus launches of Oxycodone Acetaminophen, Naltrexone, and Phentermine tablets.
Conference call on June 30, 2026 at 11:30 AM EDT; dial-in 1-800-346-7359 (domestic), conference number 98840.
Stockholders may submit financial questions by 7:00 PM EDT on June 29, 2026 via dianne@elitepharma.com.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.